We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Hercules Receives €3.5 Million EUROSTARS Grant


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Hercules Receives €3.5 Million EUROSTARS Grant"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Hercules Pharmaceuticals BV has been awarded a € 3.5 million Eurostars grant for the development of its lead drug CB7993113 for treatment of TNBC. The Eurostars grant will enable Hercules to advance CB7993113, a novel non-toxic targeted anti-cancer drug, through pre-clinical development towards clinical trials in cancer patients.

The development work will be done by a Dutch-English-Finnish-Danish-French consortium of specialist life-science companies and with researchers at Boston University in the U.S.

Hercules’ lead product, CB7993113, attacks tumors in three synergistic ways. Firstly, by inhibiting the Aryl Hydrocarbon Receptor (AHR), CB7993113 blocks spreading of the tumor via a direct effect on AHR positive tumor cells.

Secondly, it reduces the number and function of Cancer Stem Cells, which are a type of cancer cells that resist chemotherapy and often cause metastasis and relapse of cancer even after “successful” treatment.

Thirdly, CB7993113 may enhance tumor-specific immune response, which are dampened by the cancer itself. In this regard, CB7993113 is likely to act in a fashion similar to that of Check-Point inhibitors, a class of highly effective anti-cancer drugs.

CB7993113 has shown efficacy in in-vivo cancer models in which it dramatically improved survival from 25% to 90% and inhibited tumor metastasis. Once proven to be safe for human use, the drug may be tested in patients with carcinomas including TNBC, for which there is a critical unmet medical need.

Professor David Sherr, founder of Hercules comments: “I’m delighted about this grant which allows us to further develop our novel approach to treating cancer. Our lab demonstrated that the AhR plays a crucial role in driving cancer cell metastasis, resistance to therapy, and suppression of tumor-specific immune responses. Therefore we are fully committed to our mission of developing drugs targeted to this cancer Achilles heel, that would offer hope for the treatment of some of the most aggressive cancers including triple negative breast cancer.”

Advertisement